Lupin to divest entire stake in Kyowa Pharmaceutical

12 Nov 2019 Evaluate

Lupin has received approval for divestment of its entire equity interest, representing 99.82% of the issued and paid up capital, in Kyowa Pharmaceutical Industry, Japan, a step-down material subsidiary of the Company, by Nanomi BV, a wholly owned material subsidiary of the Company, by way of sale of shares, to Plutus, Japan (an entity affiliated with Unison Capital Partners IV, LPS and Unison Capital Partners IV(F), LP) at an enterprise value of JPY 57,361 million on terms and conditions agreed under a share purchase agreement. The Board of Directors of the Company at its meeting held on November 11, 2019 has approved the same.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×